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Systematic reviews aim to collate all 
empirical evidence that fits prespecified 
eligibility criteria to answer a specific 
research question. Some systematic 
reviews undertake a meta- analysis to 
statistically combine study results and 
provide a more precise estimate of treat-
ment effects. These meta- analyses are 
commonly based on aggregate data, 
extracted from publications or obtained 
from the original authors of these papers1 
but aggregating data limits the options for 
in depth analysis.
Meta- analysis of individual patient data 
(IPD) appeared in the 1990s2 to address 
these problems. A great advantage of 
IPD analysis is that it offers investigators 
the opportunity to investigate whether 
an intervention is differentially effec-
tive for different types of participants. 
Quantifying interaction effects using IPD 
increases power and generalisability of 
results and is considered the gold standard 
for subgroup analyses.3
We congratulate Hayden and 
colleagues (linked paper BJSM 2020, 
bjsports-2019-101205)4 who undertook 
an IPD to identify subgroups of patients 
who particularly benefit from exercise 
therapy for low back pain.4 From a total 
pool of 56 eligible trials, the authors 
retrieved data from 27 studies (3514 
participants). This reflects the major chal-
lenge when performing IPD analyses—
retrieving raw data from multiple trials.
Let us drill down on some specific 
barriers to successfully obtaining the ‘D’ 
in IPD—data (figure 1). The first step, 
contacting original authors, can be chal-
lenging and some authors reached do 
not respond.5 6 Moreover, authors often 
refuse to participate or report that data 
is no longer available at their institute, or 
that they do not have intellectual property 
rights to the original data. The latter is 
particularly common when pharmaceu-
tical companies own the data.5–7
Even when authors are willing to share 
data, the taming of the beast is just begin-
ning. Data regulations and governing laws 
can be quite complex. As they differ mark-
edly between countries, and most IPD 
meta- analyses include data from many 
countries, it can be extremely difficult to 
obtain a data delivery agreement signed 
by all parties. In some countries such as 
Canada and Australia, new analyses (ie, 
the IPD meta- analysis) require new ethics 
committee approval.
Once researchers have retrieved data, 
they face further challenges. Hayden and 
colleagues tried to verify the data and were 
able to replicate the main study outcomes 
of fewer than 50% of the trials. The 
authors were able to analyse 18 potential 
effect modifiers but many of these had up 
to 75% missing data (eg, ‘history of low 
back pain’). Potential effect modifiers are 
often not measured in the foundation 
studies or are inconsistently available—
this greatly constrains researchers from 
analysing potential treatment effect 
modification and is a frequent problem in 
IPD analyses.
SyStem-wIDe effortS to overcome 
Some of theSe barrIerS
What is being done to stimulate open 
access to research data? Funding agen-
cies increasingly require data be shared 
after a project is finished and in 2016 the 
Council of the European Union encour-
aged member countries to transition to an 
open science system. In the Netherlands, 
ZonMW (The Netherlands Organisation 
for Health Research and Development) 
supports FAIR (findable, accessible, 
interoperable, reusable research data), 
requiring researchers to share their data 
to contribute to future research.8 The US 
National Institutes of Health has a similar 
requirement.
Scientific journals increasingly 
encourage open access of data. BMJ has 
adopted different policies on data sharing, 
depending on the specific journal. These 
include the requirement and encour-
agement to openly and publicly make 
generated data available on publication. 
Notwithstanding, this is still voluntary in 
many of these journals. BMJ also accepts 
DataCite DOIs that make it possible to 
cite publicly available used data in refer-
ence lists.
Successful examples of studies with open 
data by design include the osteoarthritis 
(OA) initiative and the cohort hip and 
cohort knee (CHECK)- studies, two multi-
centre, longitudinal, prospective observa-
tional studies of knee and hip OA.9 10 All 
collected individual data are openly acces-
sible or available on application, resulting 
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figure 1 Steps to be taken in individual patient data approach and potential barriers and 
challenges.
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in more than 600 publications, attesting to 
the power of open data sharing.
Multiple initiatives have now been 
launched to build collaborations for the 
development of IPD banks to facilitate 
data accessibility, such as the OA Trial 
Bank for clinical OA research and the 
World COACH study for morphological 
data of the hip.11 These initiatives provide 
consistent and transparent rules of collab-
oration and agreements for sustainability 
and accessible sharing of data.
Sport Data Valley in the Netherlands 
aims to connect sport with science, govern-
ment and companies. All sport science and 
medicine related data can be uploaded 
into the repository and access rights are 
adjustable per dataset, and data ownership 
remains at the principal investigator. Such 
repositories make data widely accessible 
to a broad audience.12 Other examples 
of controlled access repositories of data 
include the  clin ical stud ydat arequest. com 
and the Yale University Open Data Access 
(YODA) project.
Although many challenges remain, the 
time investment and barriers facing IPD 
analyses should decrease in the coming 
years. We expect that data will be richer 
and more consistent given the disease- 
specific reporting standards and core data 
sets launched in many fields of research. 
However, researchers and pharmaceutical 
companies must be willing to share data 
so that the potential value of IPD analyses 
is realised. To maximise the use of indi-
vidual participant data collected in clinical 
studies is also to fulfil the ethics contract 
with the study participants (table 1).
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table 1 Critical elements to improve future individual patient data analyses
1. Change our mind- set: to openly share data is a win- win situation
2. Collect and report minimum core outcome trial data following standards for conditions of interest
3. Store annotated data for both academic and industry sponsored trials in open access repositories
4. Harmonise ethics and legal issues for data- access and reuse
5. Provide funding and guarantees for sustainable open data repositories
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